A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
← catalyst calendarNCT07803744 · readout ≤ 117 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
18estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-04
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus, Type 1
- Overweight
- Obesity
Interventions
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Acetaminophen
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen
measured Predose on Day 1 through 36 hours post dose
PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen
measured Predose on Day 1 through 36 hours post dose
PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen
measured Predose on Day 1 through 36 hours post dose
Related
LLY · their whole pipeline · Type 1 Diabetes readouts · Who in Congress owns LLY? · Executive-branch trades in LLY
LLY's other studiesmost recently updated first
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes Phase 3 · Completed
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease Phase 2 · Recruiting
- A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Phase 1 · Recruiting
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Phase 3 · Recruiting
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Phase 1 · Recruiting
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed